Amgen’s Kyprolis’ new dosing option gets FDA nod

The Food and Drug Administration has approved Amgen’s Kyprolis (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone a ” once-weekly Kd70 a ” for patients with relapsed or refractory multiple myeloma. “While great progress has been made in the last decade, multiple myeloma remains an incurable disease characterized by a recurring pattern of remission and relapse, and it is important that patients have treatment options that meet their individual needs,” David Siegel, chief of the division of multiple myeloma at John Theurer Cancer Center, said. “The availability of a more convenient once-weekly dosing regimen, with superior efficacy, comparable safety and longer duration of therapy versus the twice-weekly regimen studied in the trial could allow patients to spend more time outside of the infusion center.”